Home > Dermatology > AAD 2022 > Posters > AD treatment during the pandemic: dupilumab does not raise COVID-19 infection risk

AD treatment during the pandemic: dupilumab does not raise COVID-19 infection risk

Presented By
Dr Brian Rankin, University of Calgary, Canada
Conference
AAD 2022
Trial
Cohort study
Patients treated with dupilumab for atopic dermatitis (AD) demonstrated a lower COVID-19 rate compared with the incidence of SARS-CoV-2 infection in the general public. This finding of a multicentre, retrospective study is consistent with existing recommendations to carry on with treatment. As long as no signs or symptoms of a SARS-CoV-2 infection are present, the continuation of a biologic treatment with dupilumab for AD is recommended [1,2]. Also, starting an indicated therapy with the agent should not be postponed due to the COVID-19 pandemic. Yet, the discussion is still ongoing about the possible effect of biologic treatment for AD on SARS-CoV-2 infection incidence and outcome prospects [3]. To gain further insight, a Canadian, multicentre cohort study investigated patients who were followed at academic centres and community practices from 11 March 2020 until 30 April 2021. Included patients were all treated with dupilumab for AD, asthma, and/or nasal...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on